On November 17, 2023, Cuu Long Pharmaceutical Joint Stock Company (DCL) successfully organized the OGSM Roll-Out 2024 Strategy Conference. The conference reviewed the OGSM 2023 results and approved the OGSM and action plan for 2024.
This is one of DCL’s annual activities, helping the Board of Directors and all employees analyze the results achieved in 2023 and plan more precise strategies for 2024 to maximize the company’s strength and create breakthrough achievements.
The conference provided an overview of OGSM Roll-Out 2023.
Representatives from 10 departments including: Manufacturing Division; Capsule Business; Vikimco Business; ETC Business; OTC Business; Business Development; Marketing; Human Resources; Quality Management; Finance, Accounting & Project Planning reported on the 2023 work results, presented plans and goals for 2024, and received feedback and evaluation from the DCL Board of Directors.
DCL departments highlighted their goals for 2024.
Mr. Luong Trong Hai – CEO of Cuu Long Pharmaceutical Joint Stock Company, noted that 2023 was a challenging but effortful year for the company’s leadership and employees. Heading into 2024, DCL sets the goal to maintain growth momentum, collective determination, passion, professionalism, and efficiency. To achieve the 2024 targets, DCL aims for a net revenue of 1,528 billion VND and a pre-tax profit of 170 billion VND.
The consolidated financial report for Q3/2023 shows promising results. By the end of Q3, DCL achieved over 262 billion VND in revenue, up 4.55% compared to the same period; total assets increased from 2,105 billion VND to over 2,115 billion VND; equity increased from 1,391 billion VND to over 1,421 billion VND.
In the empty capsule production and supply segment, Cuu Long Pharmaceutical continues to maintain its market share in Vietnam and is expanding its Vicancap factory as scheduled. By January 2024, with the operation of capsule line 5, the supply capacity is expected to reach 9.6 billion capsules/year, equivalent to about 800 million capsules/month.
In the medical equipment sector, with the goal of enhancing production capacity and meeting domestic demand while aiming for international markets, DCL continues to ensure the construction progress of the Benovas Medical Equipment Manufacturing Plant. The project spans 11,000m2, with a total investment of 373 billion VND, divided into two phases and expected to be operational by Q2/2024.
In the Pharmaceutical segment, DCL is investing in an EU – GMP standard pharmaceutical plant with a total investment of 1,035 billion VND. The plant’s production capacity for medicines and pharmaceutical products is 1.6 billion products/year. Once the project is completed and operational, it will mark a significant step forward for Cuu Long Pharmaceutical in particular, contributing to the development of Vietnam’s pharmaceutical industry in general.
The Board of Directors and employees of DCL are determined to excellently achieve the 2024 goals.
With the spirit of “Determined to maintain growth momentum; united – professional – more efficient” in all activities, the Board of Directors and all employees have shown commitment and joint action to create new breakthroughs, helping Cuu Long Pharmaceutical Joint Stock Company move closer to its vision of becoming the most highly regarded Vietnamese pharmaceutical company by patients, partners, and employees through innovative, accessible products and excellent care.
